Sun Pharma announced on Tuesday that its experimental drug, SCD-044, failed to meet primary endpoints in two mid-stage clinical trials targeting moderate-to ... falling as much as 2% to an intraday ...

Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for psoriasis and atopic dermatitis. The company has decided to ...

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. ... Hero Moto, M&M, others tumble up to 2%, dragging Nifty Auto after a three-day rise.

Overall, there were 9,535 diagnoses of what is described as early-stage syphilis in England in 2024, up 2% on 2023. But the overall figure for syphilis, including what is called late-stage ...